Extracellular vesicles in osteoarthritis: mechanisms, biomarkers and translational strategies

Osteoarthritis (OA) is a whole-joint disorder characterized by cartilage degeneration, synovial inflammation, subchondral bone remodeling, pain and progressive functional impairment. Current management remains largely symptomatic, and no widely accepted disease-modifying therapy is available. Extracellular vesicles (EVs) mediate intercellular communication by transferring regulatory RNAs, proteins, lipids, metabolites and other bioactive molecules. Their effects depend on the source and state of the donor cell, cargo composition, recipient phenotype, dose and disease context. EVs released by inflamed or mechanically stressed joint tissues can amplify matrix catabolism, inflammasome activation, senescence, defective autophagy and osteochondral crosstalk. By contrast, selected mesenchymal stromal cell (MSC)-derived, preconditioned, engineered or biomaterial-delivered EV preparations show reparative and immunomodulatory activity in preclinical models. Synovial-fluid and circulating EV profiles are also being investigated as biomarkers, although independent validation remains limited. In this narrative review, we integrate EV-mediated communication across cartilage, synovium, subchondral bone and immune compartments. We also critically assess the evidence for OA biomarkers and cell-free therapies. Current evidence supports EVs as candidate biomarkers and experimental therapeutic platforms, but does not yet establish their clinical diagnostic utility or therapeutic efficacy in OA. Translation requires independent biomarker validation, standardized EV characterization and dosing, mechanism-linked potency assays, and controlled clinical trials that distinguish symptomatic improvement from structural disease modification.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-12
DOI
https://doi.org/10.3389/fimmu.2026.1929908
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Extracellular vesicles in osteoarthritis: mechanisms, biomarkers and translational strategies

Zhenan Qu, Hong Zhang, Bocheng Zhang, Bingxin Liu et al.
Frontiers in Immunology
Extracellular vesicles in disease
article

Extracellular vesicles in osteoarthritis: mechanisms, biomarkers and translational strategies

Zhenan Qu, Hong Zhang, Bocheng Zhang, Bingxin Liu, Xiaoyuan Tian
article en

Abstract

Osteoarthritis (OA) is a whole-joint disorder characterized by cartilage degeneration, synovial inflammation, subchondral bone remodeling, pain and progressive functional impairment. Current management remains largely symptomatic, and no widely accepted disease-modifying therapy is available. Extracellular vesicles (EVs) mediate intercellular communication by transferring regulatory RNAs, proteins, lipids, metabolites and other bioactive molecules. Their effects depend on the source and state of the donor cell, cargo composition, recipient phenotype, dose and disease context. EVs released by inflamed or mechanically stressed joint tissues can amplify matrix catabolism, inflammasome activation, senescence, defective autophagy and osteochondral crosstalk. By contrast, selected mesenchymal stromal cell (MSC)-derived, preconditioned, engineered or biomaterial-delivered EV preparations show reparative and immunomodulatory activity in preclinical models. Synovial-fluid and circulating EV profiles are also being investigated as biomarkers, although independent validation remains limited. In this narrative review, we integrate EV-mediated communication across cartilage, synovium, subchondral bone and immune compartments. We also critically assess the evidence for OA biomarkers and cell-free therapies. Current evidence supports EVs as candidate biomarkers and experimental therapeutic platforms, but does not yet establish their clinical diagnostic utility or therapeutic efficacy in OA. Translation requires independent biomarker validation, standardized EV characterization and dosing, mechanism-linked potency assays, and controlled clinical trials that distinguish symptomatic improvement from structural disease modification.

Frontiers in ImmunologyVol. 17
Dalian Medical University (CN), Second Affiliated Hospital of Dalian Medical University (CN), Affiliated Zhongshan Hospital of Dalian University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Liaoning Province, Department of Education of Liaoning Province
Good health and well-being
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon